Amphastar Pharmaceuticals Future Growth
Future criteria checks 2/6
Amphastar Pharmaceuticals is forecast to grow earnings and revenue by 6.7% and 7.8% per annum respectively. EPS is expected to grow by 4.5% per annum. Return on equity is forecast to be 24.8% in 3 years.
Key information
6.7%
Earnings growth rate
4.5%
EPS growth rate
Pharmaceuticals earnings growth | 23.9% |
Revenue growth rate | 7.8% |
Future return on equity | 24.8% |
Analyst coverage | Good |
Last updated | 22 Nov 2024 |
Recent future growth updates
Recent updates
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Prospects Need A Boost To Lift Shares
Dec 16Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Nov 28Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)
Oct 25Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)
Sep 15Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines
Sep 12Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?
Aug 27Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 05Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Jul 01Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
May 30Amphastar Pharmaceuticals: Buy When Fear Is Overblown
May 30Reassessing Amphastar Pharmaceuticals
May 15Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Mar 04Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
Jan 04Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
Dec 20Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
Dec 03Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued
Sep 03These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Aug 17Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching
Jun 02We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
May 11Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price
Mar 02Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?
Feb 07Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?
Jan 24Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Nov 02Amphastar: A Pharmaceutical Growth Stock
Oct 06Amphastar wins FDA approval for Epinephrine pre-filled syringes
Aug 16Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond
Aug 08Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 24Amphastar generic vasopressin for increasing blood pressure gets FDA approval
Jul 19Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 873 | 209 | 222 | 286 | 5 |
12/31/2025 | 807 | 186 | 202 | 249 | 6 |
12/31/2024 | 738 | 174 | 169 | 222 | 6 |
9/30/2024 | 724 | 158 | 170 | 208 | N/A |
6/30/2024 | 713 | 167 | 178 | 213 | N/A |
3/31/2024 | 676 | 155 | 161 | 198 | N/A |
12/31/2023 | 644 | 138 | 145 | 184 | N/A |
9/30/2023 | 601 | 135 | 140 | 175 | N/A |
6/30/2023 | 541 | 102 | 100 | 131 | N/A |
3/31/2023 | 519 | 93 | 51 | 79 | N/A |
12/31/2022 | 499 | 91 | 65 | 89 | N/A |
9/30/2022 | 485 | 77 | 90 | 114 | N/A |
6/30/2022 | 477 | 91 | 70 | 97 | N/A |
3/31/2022 | 455 | 81 | 100 | 126 | N/A |
12/31/2021 | 438 | 62 | 71 | 98 | N/A |
9/30/2021 | 413 | 36 | 45 | 74 | N/A |
6/30/2021 | 384 | 10 | 52 | 81 | N/A |
3/31/2021 | 368 | 2 | 45 | 79 | N/A |
12/31/2020 | 350 | 1 | 23 | 57 | N/A |
9/30/2020 | 337 | 7 | 13 | 46 | N/A |
6/30/2020 | 334 | 4 | -11 | 25 | N/A |
3/31/2020 | 327 | 52 | 12 | 47 | N/A |
12/31/2019 | 322 | 49 | 0 | 42 | N/A |
9/30/2019 | 329 | 52 | 3 | 46 | N/A |
6/30/2019 | 324 | 53 | 27 | 73 | N/A |
3/31/2019 | 316 | 2 | -23 | 26 | N/A |
12/31/2018 | 295 | -6 | -4 | 38 | N/A |
9/30/2018 | 265 | -7 | -5 | 38 | N/A |
6/30/2018 | 248 | -9 | N/A | 25 | N/A |
3/31/2018 | 242 | -4 | N/A | 25 | N/A |
12/31/2017 | 240 | 4 | N/A | 39 | N/A |
9/30/2017 | 243 | 0 | N/A | 43 | N/A |
6/30/2017 | 250 | 4 | N/A | 42 | N/A |
3/31/2017 | 252 | 9 | N/A | 47 | N/A |
12/31/2016 | 255 | 10 | N/A | 39 | N/A |
9/30/2016 | 269 | 21 | N/A | 28 | N/A |
6/30/2016 | 268 | 14 | N/A | 30 | N/A |
3/31/2016 | 254 | 0 | N/A | 23 | N/A |
12/31/2015 | 252 | -3 | N/A | 11 | N/A |
9/30/2015 | 230 | -13 | N/A | 20 | N/A |
6/30/2015 | 226 | -15 | N/A | 30 | N/A |
3/31/2015 | 221 | -10 | N/A | 28 | N/A |
12/31/2014 | 210 | -11 | N/A | 21 | N/A |
9/30/2014 | 209 | -6 | N/A | 17 | N/A |
6/30/2014 | 209 | -1 | N/A | 4 | N/A |
3/31/2014 | 223 | 8 | N/A | 24 | N/A |
12/31/2013 | 230 | 12 | N/A | 31 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMPH's forecast earnings growth (6.7% per year) is above the savings rate (2.6%).
Earnings vs Market: AMPH's earnings (6.7% per year) are forecast to grow slower than the US market (15.2% per year).
High Growth Earnings: AMPH's earnings are forecast to grow, but not significantly.
Revenue vs Market: AMPH's revenue (7.8% per year) is forecast to grow slower than the US market (9.1% per year).
High Growth Revenue: AMPH's revenue (7.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AMPH's Return on Equity is forecast to be high in 3 years time (24.8%)
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 10:26 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Amphastar Pharmaceuticals, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Gary Nachman | BMO Capital Markets Equity Research |
Jason Matthew Gerberry | BofA Global Research |
Timothy Chiang | Capital One Securities, Inc. |